RxDoctor Payments Data

Kenneth Civello, MD

Clinical Cardiac Electrophysiology · Baton Rouge, LANPI 1699745562

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.5% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $13,030 and has fallen 92.5% since, to $980 in 2025.

$29,568in general payments, 2019–2025

Across 445 payments — averaging $66.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Atricure, Inc.$3K
  • Boston Scientific$1K
  • Johnson & Johnson$924
  • Pfizer$690
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$464
  • plus $3K from 41 others
$39,608in research payments, 2019–2025

Across 47 payments — averaging $842.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$17K
  • Atricure, Inc.$10K
  • Medical Device Business Services, Inc.$7K
  • Abbott$5K

What the payments were for

  • Consulting fees$2,1007%
  • Speaking & faculty fees$12,70043%
  • Travel & lodging$4,20514%
  • Food & beverage$10,53236%
  • Education$140%
  • Other$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,568 in reported general payments places this provider in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

See all clinical cardiac electrophysiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$242,631
Medicare patients
1,046
Services billed
3,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban580$640,309
XareltoRivaroxaban146$166,404
OpsumitMacitentan12$144,544
JardianceEmpagliflozin135$127,145
EntrestoSacubitril/Valsartan75$84,363
Repatha SureclickEvolocumab95$69,221
MultaqDronedarone Hcl27$36,080
Dofetilide143$24,824
FarxigaDapagliflozin Propanediol22$20,142
NexlizetBempedoic Acid/Ezetimibe13$9,916
Flecainide Acetate179$9,508
Metoprolol Succinate441$8,729
Atorvastatin Calcium319$4,485
Acebutolol Hcl50$3,651
Amiodarone Hcl46$2,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$690$640,309580 claims
Johnson & JohnsonXarelto$924$166,404146 claims
Boehringer IngelheimJardiance$38$127,145135 claims
NovartisEntresto$383$84,36375 claims
Sanofi-aventis U.S. LLCMultaq$129$36,08027 claims
AstraZenecaFarxiga$152$20,14222 claims
Esperion Therapeutics, Inc.Nexlizet$19$9,91613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

Other clinical cardiac electrophysiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →